Videos

Presented by: Fujifilm Cellular Dynamics, Inc. and Nanion Technologies GmbH

Speakers: T.K. Feaster, PhD, Product Manager, Fujifilm Cellular Dynamics, Inc. and Sonja Stoelzle-Feix, PhD, Director, Scientific Affairs, Nanion Technologies GmbH

Part I: 12:30 – 12:45 pm
Dr. T.K. Feaster will discuss the predictive power of human iPSC-derived cells for in vitro toxicity testing. He will highlight toxicology, drug screening, and disease models. Demonstrating increased functionality and throughput valuable for identifying liabilities early in preclinical safety programs.

Part II: 12:50 – 1:20 pm
Dr. Sonja Stoelzle-Feix will discuss the effects of “CiPA drugs” on excitation-contraction coupling in iCell Cardiomyocytes². She will describe the evaluation of the proarrhythmic potential of 23 blinded drugs on hiPSC-CMs using iCell Cardiomyocytes² and the Nanion CardioExcyte 96 at different sites. Ion channel data and myocyte behavior will be discussed and aligned.

(Oct 2, 2018)

Kile Mangan, Cellular Dynamics International at The Biophysical Society 2018 Annual Meeting, Exhibitor Presentation, San Francisco, CA

Dr. Kile Mangan from Cellular Dynamics International will follow with a talk on utilizing novel functional assays with high-definition multielectrode arrays (HD-MEAs: MaxWell Biosystems) to uncover phenotypic differences in neurons harboring single-nucleotide disease mutations (alpha synuclein A53T Parkinson’s Disease) or in normal control following pharmacological perturbation.

(Feb 18, 2018)

Coby Carlson Chris McMahon, Cellular Dynamics International at the ISSCR 2017 Innovation Showcase in Boston, MA

Parkinson’s disease (PD) affects approximately 1% of people over the age of 65 and is the second most common neurodegenerative disorder after Alzheimer’s disease. The advent of induced pluripotent stem cell (iPSC) technology now grants us access to previously unattainable cell types in the human brain. In this presentation, we will discuss how stem cells are being used not only to study PD in the lab, but also to develop treatments for PD using cells as therapies. Specifically, we have created an isogenic disease model for PD using human iPSC-derived midbrain dopaminergic neurons and have developed in vitro assays for comparative analysis of mitochondrial bioenergetics, calcium handling, and network-level electrophysiology. In the regenerative medicine space, we are actively manufacturing cGMP HLA “superdonor” iPSC lines for universal utility and will provide an update on our progress in developing iPSC-derived cellular therapies, including our program to treat PD by engrafting human midbrain dopaminergic neurons.

(Jun 15, 2017)

Chris Parker, Cellular Dynamics International at SLAS2016 in San Diego, Presented by LabTube

Part of the “LabTube Meets…” series, Chris Parker, Executive VP and Chief Business Officer of Cellular Dynamics describes the recently launched MyCell Disease & Diversity Products. Chris was interviewed at SLAS 2016 in San Diego.

(Jan 25, 2016)

Tutorial presented by Nicolas Pierre, Cisbio Bioassays and Coby Carlson, Cellular Dynamics International at SLAS2016 in San Diego

This tutorial details how the combination of iPSC-derived cell types from Cellular Dynamics International (CDI) have been used with HTRF assays from Cisbio to dissect various cell signaling events and to quantify biomarker production or cytokine release, particularly around cell stress and inflammation.

(Jan 25, 2016)